These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 21523722)

  • 61. 2,2'-Methylenebis (6-tert-butyl 4-methylphenol) enhances the antitumor efficacy of belotecan, a derivative of camptothecin, by inducing autophagy.
    Jang M; Kim H; Park R; Jo D; Lee EJ; Oh WK; Park J
    Oncotarget; 2017 Dec; 8(70):115068-115078. PubMed ID: 29383142
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Which is the best foot to put forward in recurrent ovarian cancer?
    Rose PG
    Cancer; 2012 Jul; 118(13):3229-31. PubMed ID: 22072331
    [No Abstract]   [Full Text] [Related]  

  • 63. Breast Necrosis after Chemotherapy for Recurrent Ovarian Cancer: Report of a Case and Review of the Literature.
    Matloob R; Alikhasi A; Shirkhoda M; Najafi M
    Breast J; 2015; 21(4):418-22. PubMed ID: 25912969
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Recurrent ovarian cancer: evidence-based treatment.
    Ozols RF
    J Clin Oncol; 2002 Mar; 20(5):1161-3. PubMed ID: 11870155
    [No Abstract]   [Full Text] [Related]  

  • 65. Plant associated fungal endophytes as a source of natural bioactive compounds.
    Rai N; Kumari Keshri P; Verma A; Kamble SC; Mishra P; Barik S; Kumar Singh S; Gautam V
    Mycology; 2021; 12(3):139-159. PubMed ID: 34552808
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Natural Compounds as Therapeutic Agents: The Case of Human Topoisomerase IB.
    Ottaviani A; Iacovelli F; Fiorani P; Desideri A
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923641
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?
    Li F; Jiang T; Li Q; Ling X
    Am J Cancer Res; 2017; 7(12):2350-2394. PubMed ID: 29312794
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Melatonin Synergizes the Chemotherapeutic Effect of Cisplatin in Ovarian Cancer Cells Independently of MT1 Melatonin Receptors.
    Zemła A; Grzegorek I; Dzięgiel P; Jabłońska K
    In Vivo; 2017; 31(5):801-809. PubMed ID: 28882945
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comparison of the efficacy between topotecan- and belotecan-, a new camptothecin analog, based chemotherapies for recurrent epithelial ovarian cancer: a single institutional experience.
    Kim HS; Park NH; Kang S; Seo SS; Chung HH; Kim JW; Song YS; Kang SB
    J Obstet Gynaecol Res; 2010 Feb; 36(1):86-93. PubMed ID: 20178532
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer.
    Nam EJ; Kim JW; Kim JH; Kim S; Kim SW; Jang SY; Lee DW; Jung YW; Kim YT
    Am J Clin Oncol; 2010 Jun; 33(3):233-7. PubMed ID: 19745693
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: results of a single-institutional phase II study.
    Kang H; Kim TJ; Lee YY; Choi CH; Lee JW; Bae DS; Kim BG
    Gynecol Oncol; 2009 Aug; 114(2):210-4. PubMed ID: 19446320
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer.
    Matulonis UA; Horowitz NS; Campos SM; Lee H; Lee J; Krasner CN; Berlin S; Roche MR; Duska LR; Pereira L; Kendall D; Penson RT
    J Clin Oncol; 2008 Dec; 26(35):5761-6. PubMed ID: 19001330
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer.
    Choi CH; Lee YY; Song TJ; Park HS; Kim MK; Kim TJ; Lee JW; Lee JH; Bae DS; Kim BG
    Cancer; 2011 May; 117(10):2104-11. PubMed ID: 21523722
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Treatment of platinum-resistant ovarian cancer].
    Onishi Y; Nakamura T; Hatae M
    Nihon Rinsho; 2004 Oct; 62 Suppl 10():554-9. PubMed ID: 15535307
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.